References
- King, C. R., Kraus, M. H. and Aaronson, S. A. : Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229, 974 (1985). https://doi.org/10.1126/science.2992089
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. and McGuire, W. L. : Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177 (1987). https://doi.org/10.1126/science.3798106
- Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R. and Aaronson S. A. : erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237, 178 (1987). https://doi.org/10.1126/science.2885917
- Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G. and Keith, D. E. : Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707 (1989). https://doi.org/10.1126/science.2470152
- Moasser, M. M. : The oncogene HER-2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469 (2007). https://doi.org/10.1038/sj.onc.1210477
- Press, M. F. and Lenz, H. J. : EGFR, HER-2 and VEGF pathways, validated targets for cancer treatment. Drugs 67, 2045 (2007). https://doi.org/10.2165/00003495-200767140-00006
- Hortobagyi, G. N. : Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol. 28(6 Suppl 18), 43 (2001). https://doi.org/10.1053/sonc.2001.29710
- Clynes, R. A., Towers, T. L. and Presta, L. G. : Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443 (2000). https://doi.org/10.1038/74704
- Maple, L., Lathrop, R., Bozich, S., Harman, W., Tacey, R., Kelley, M. and Danilkovitch-Miagkova, A. : Development and validation of ELISA for Herceptin detection in human serum. J. Immunol. Methods 295, 169 (2004). https://doi.org/10.1016/j.jim.2004.09.012
- Sias, P. E., Kotts, C. E., Vetterlein, D., Shepard, M. and Wong, W. L. : ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J. Immunol. Methods 132, 73 (1990). https://doi.org/10.1016/0022-1759(90)90400-P
- Piechocki, M. P., Pilon, S. A. and Wei, W. Z. : Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J. Immunol. Methods 259, 33 (2002). https://doi.org/10.1016/S0022-1759(01)00487-2
- Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C. and Norton, L. : Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737 (1996). https://doi.org/10.1200/JCO.1996.14.3.737
- Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A. and Slamon, D. J. : Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/ neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659 (1998).
- Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F. and Slamon, D. : Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241 (1999). https://doi.org/10.1038/sj.onc.1202526
- Leyland-Jones, B., Gelmon, K., Ayoub, J. P., Arnold, A., Verma, S., Dias, R. and Ghahramani, P. : Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J. Clin. Oncol. 21, 3965 (2003). https://doi.org/10.1200/JCO.2003.12.109
- Baselga, J., Carbonell, X., Castañeda-Soto, N. J., Clemens, M., Green, M., Harvey, V., Morales, S., Barton, C. and Ghahramani, P. : Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin. Oncol. 23, 2162 (2005). https://doi.org/10.1200/JCO.2005.01.014
- Bruno, R., Washington, C. B., Lu, J. F., Lieberman, G., Banken, L. and Klein, P. : Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 56, 361 (2005). https://doi.org/10.1007/s00280-005-1026-z